knowledge -WSS

knowledge

author：explore 2025-09-01 06:01:57 - browse：486

Pfizer and Moderna aren’t the only vaccine money-makers. Much of the revenue and profits from Covid-19 vaccines are flowing behind the scenes, going to the contract manufacturers and clinical-trial organizers that turn the shots from lab-bench theory to mass-produced reality.

Both AstraZeneca and Johnson & Johnson publicly committed to not profiting off their products during the pandemic — though AstraZeneca has reserved the right to declare the pandemic over on July 1, even if the World Health Organization has not. Pfizer and Moderna made no such pledge, with Pfizer expected to make $15 billion in vaccine-related revenue this year, while Moderna is forecasting $18.4 billion in vaccine sales.

Contractors hired to test and manufacture these vaccines have enjoyed a share of the profits without the same level of public scrutiny.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Why Medicare shouldn’t cover every FDA

focus

leisure time

WSS

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Why you shouldn’t ask, “What country has the best health care?”

Scientists inch closer to single

Trump indictment: Who are the 'co

What the airline industry can learn from medicine

FTC sues over Novant Health acquisition of two N.C. hospitals

hotspot

knowledge

knowledge

Medical records are filled with copy

What to expect as Trump is arraigned on his Jan 6. indictment

Medicare details structure of new drug price negotiation program

Vertex non

New air purifier tech could be key to improving indoor air quality

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Dobbs anniversary: the lost opportunity of abortion as health care

Philips to halt sales of sleep apnea machines in U.S.

Medical leaders decry Supreme Court decision on affirmative action

Medicare Advantage insurers face 0.2% cut to 2025 payments

entertainment

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Merck, Johnson & Johnson CEOs will testify on high drug prices

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Biogen walks away from Aduhelm, years after polarizing approval

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Wikipedia

focus

leisure time

focus